Jazz Pharmaceuticals plc (JAZZ)
Valor JustoFundamental
70
Preço
$231.52
Capitalização de Mercado
$15.03B
Parte 1 · Quanto vale a empresa
Visão Geral
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Zepzelca for the treatment of metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy; Ziihera to treat HER2-positive biliary tract cancers; Modeyso for the treatment of diffuse midline glioma harboring an H3 K27M mutation; and Defitelio to treat severe veno-occlusive disease. It also develops Zanidatamab in Phase 3 trial to treat HER2-positive gastroesophageal adenocarcinoma (GEA) and biliary tract cancers (BTC); Dordaviprone to treat H3 K27M-mutant diffuse glioma; and Vyxeos for the treatment of newly-diagnosed therapy-related acute myeloid leukemia. In addition, the company is developing Zanidatamab to treat neoadjuvant and adjuvant breast cancer; Vyxeos for the treatment of High-risk MDS, newly diagnosed untreated patients with high-risk AML, and De novo intermediate or adverse risk AML stratified by genomics; and JZP3507 to treat pheochromocytoma and paraganglioma that are in Phase 2 clinical trials. Further, it develops JZP815 to treat Raf and Ras mutant tumors; JZP898 for the IFN INDUKIN molecule in solid tumors; and JZP047 to treat absence epilepsy that are in Phase 1 clinical trials. The company collaboration agreements with Redx Pharma plc, Autifony Therapeutics Limited, Zymeworks Inc., Sumitomo Pharma Co., Ltd., Werewolf Therapeutics, Inc; and AbCellera Biologics Inc. Jazz Pharmaceuticals plc was founded in 2003 and is headquartered in Dublin, Ireland.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
Balanço & Liquidez
Receita
$4.60B
Últimos 12 meses (até 30/06/2026)
Resultado Líquido
$941M
Últimos 12 meses (até 30/06/2026)
Fluxo de Caixa Livre
$1.30B
Capital Próprio Total
$4.32B
Passivo Total
$7.34B
Rácio de Liquidez
1.78
Cobertura de Juros
-
Dívida/EBITDA
-
Resultados Por Ação
Receita & Resultado Líquido
Fluxo de Caixa Livre
Decomposição dos Resultados
Demonstração histórica
Margens ao longo do tempo
A dívida ao longo do tempo
Quanto pesa a dívida
Grelha do crescimento
Crescimento — Receitas
Estimativa de Valor Justo
Valor Justo
$257.79
Preço Atual
$231.52
Margem de Segurança
+10.2%
Intervalo de Valor Justo
$167.57 - $348.02
Dispersão entre os métodos de avaliação utilizados, não um intervalo de confiança calibrado estatisticamente.
Métodos de Estimativa
Métricas de Avaliação
Rácio P/E
15.83
ROE
-8.2%
Rácio P/B
3.13
P/FCF
9.44
Margem Bruta
-
ROIC
8.0%
Radar de Rentabilidade
Criação de Valor (Vantagem Competitiva)
ROIC
8.0%
WACC
6.2%
ROIC − WACC
+1.8 pp
O ROIC supera o custo do capital — a empresa está a criar valor para os acionistas.
Critérios de Análise Fundamental
Aprovado (17)
- Price CAGR 7.98%
- ROIC 8.0%
- P/FCF 9.44
- Debt/Equity ratio
- Operating Margin 19.5%
- Positive Free Cash Flow
- CapEx intensity
- Current Ratio
- Return on Tangible Assets
- ROE 21.4%
- Revenue Growth 5Y 12.5%
- Analyst Consensus 92% Buy
- Earnings Surprise avg 15.3%
- Earnings Quality (OCF/NI) 1.77
- Share Dilution -5.8%
- Net Margin Trend 20.4% vs -9.9%
- Piotroski F-Score 5/9
Reprovado (5)
- EPS shows upward trend
- P/B Ratio 3.13
- Low reliance on intangibles
- Price below Graham Number
- DCF valuation (Overvalued)
Indisponível (5)
- Gross Margin NaN%
- Dividend Payout NaN%
- Interest Coverage
- Debt/EBITDA
- PEG Ratio (need PE > 0 and growth > 0)
Piotroski F-Score
Sinais mistos: algumas áreas requerem atenção
Qualidade dos Resultados
Alta qualidade: resultados respaldados por caixa
Diluição de Ações
A recomprar ações. Favorável ao acionista
Participações institucionais
Não há declarações institucionais para esta empresa.
Governação
Equipa Executiva
| Nome | Cargo | Idade |
|---|---|---|
| Mr. Bruce C. Cozadd | Co-Founder & Chairman | 61 |
| Ms. Renee D. Gala | President, CEO & Director | 53 |
| Mr. Philip L. Johnson | Executive VP & CFO | 61 |
| Ms. Neena M. Patil J.D. | Executive VP & Chief Legal Officer | 50 |
| Dr. Robert Iannone M.D. | Executive VP, Chief Medical Officer and Global Head of Research & Development | 58 |
| Ms. Samantha Pearce | Executive VP & Chief Commercial Officer | 59 |
| Ms. Patricia Carr | Senior VP & Chief Accounting Officer | 54 |
| Mr. John D. Bluth | Head of Investor Relations | 52 |
| Ms. Heidi Manna | Executive VP & Chief People Officer | 54 |
| Dr. Jed Black M.D. | Senior Vice President of Sleep & CNS Medicine | - |
Risco de Auditoria
8
Risco do Conselho
4
Risco de Remuneração
5
Risco dos Direitos dos Acionistas
3
Parte 2 · O preço e o momento de entrar
Esta parte não serve para saber se a empresa vale: serve para escolher quando comprá-la, depois que os fundamentos te convenceram. Dentro: análise técnica, potencial, quedas históricas, exposição gama.
Documentos
- Ver documento
Relatório anual (10-K)
Uma visão anual do negócio, dos resultados financeiros e dos riscos da empresa.
Arquivado em 2026-02-24
- Ver documento
Relatório trimestral (10-Q)
Uma atualização sobre o desempenho financeiro dos últimos três meses.
Arquivado em 2026-08-03
- Ver documento
Relatório de fato relevante (8-K)
Um aviso sobre um fato relevante, como uma mudança na liderança ou um grande anúncio.
Arquivado em 2026-09-23
via SEC EDGAR
Histórico de Resultados
via SEC EDGAR
Latest News
Recent headlines for JAZZ, sourced from Markets Gazette.
- 6/17/2026POSITIVEJazz Pharmaceuticals Gains Oncology Firepower Through AbCellera Collaboration
Jazz Pharmaceuticals has entered into a strategic collaboration with AbCellera to discover and develop novel cancer therapies. This partnership aims to leverage AbCellera's AI-powered antibody discovery platform to identify potential drug candidates for challenging oncology targets. Despite a recent setback in a Zepzelca trial, this move signals Jazz's commitment to strengthening its oncology pipeline. Analysts remain optimistic, maintaining positive price targets, suggesting that this collaboration could be a significant catalyst for future growth and value creation for shareholders.
via Markets Gazette